A study led by the Agency for Science, Technology and Research's (A*STAR) Genome Institute of Singapore (GIS) and Infectious Diseases Labs (ID Labs) has identified a gene, KCNJ15, that is associated with helping our immune system fight tuberculosis (TB), and potentially other infectious diseases. The research was published in Nature Microbiology on 31 January 2022.

The World Health Organization (WHO), the UN High Commissioner for Refugees (UNHCR) and the U.S. Centers for Disease Prevention and Control (CDC) will host a special #EndTB webinar on 2 March 2022 to launch an interagency field guide on TB prevention and care among refugees and other populations in humanitarian settings.

A brief, released by Treatment Action Group, outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.

The Stop TB Partnership and partners call on high TB burden countries to invest in interventions that overcome the prevalent human rights barriers, currently diminishing the effectiveness of national TB control efforts.

Three investigational drug regimens to treat drug-resistant tuberculosis (TB) were superior to standard of care, with fewer unfavorable outcomes and a shorter treatment time, a researcher said.

TB Vax ARM launches a campaign calling on the European leadership to fulfil their political and funding commitment to deliver new vaccines to end TB by 2030.

SAN ANTONIO (February 15, 2022) – Two weeks makes a big difference in treating the animal version of HIV and latent tuberculosis, researchers from Texas Biomedical Research Institute, Southwest National Primate Research Center and colleagues report this month in the Journal of Clinical Investigation. The finding is another piece in the puzzle of the complex interaction between HIV and tuberculosis (TB), and can help advance development of therapies and a combined vaccine for the two diseases in humans.

Following the publication in 2021 of the Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, which provides a reference standard for the interpretation of mutations conferring resistance to all first-line and a variety of second-line drugs, the World Health Organization (WHO) is now in the process of updating the catalogue to accommodate additional evidence of resistance linked to genotype.

As part of International Social Justice Day, on 18 February 2022, the Stop TB Partnership, the Global Fund Communities Delegation and the O'Neill Institute for Global & National Health Law will host an event that will bring together global health and human rights leaders, TB communities and partners to reflect on release of recent peer-reviewed evidence on TB and human rights, coupling reflections on this evidence with a dialogue on the urgent need to scale up investments to overcome human rights barriers to TB services.

Treatment with high-dose rifamycin (HDR)-based regimens was not associated with an increased risk for severe adverse events (SAE) compared with standard-dose rifamycin (SDR)-based regimens among patients with tuberculosis (TB) infection, according to results of a study published in Thorax.